THEO · BOA Acquisition Corp. II
Substantial doubt about the company's ability to continue as a going concern.
“The Company has incurred and expects to incur significant costs in pursuit of the Company's acquisition plans, and has one year from the IPO date to complete a Business Combination. These conditions raise substantial doubt about the Company's ability to continue as a going concern, for a period of time within one year after the date that the financial statements are issued. The Sponsor or an affiliate of the Sponsor, or certain of the Company's officers and directors may, but are not obligated to, provide the Company Working Capital Loans (as defined in Note 6). Management plans to address this uncertainty through an initial Business Combination. There is no assurance that the Company's plans to consummate a Business Combination will be successful within the Combination Period.”View the 10-Q filed Aug 26, 2026
Price & Indicators
The closing range uses available history since Aug 14, 2026; less than a full year is stored.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Shell Companies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
THEO
this stock
BOA Acquisition Corp. II
|
$204.87M | — | — | — | — |
|
CLUS
Cluster Group Holdings Ltd Co
|
$8.00B | — | — | — | — |
|
CCXI
Churchill Capital Corp XI
|
$738.58M | — | — | — | 6.0% |
|
DMII
Drugs Made In America Acquisition II Corp.
|
$647.83M | +2.7% | — | — | 0.2% |
|
BCSS
Bain Capital GSS Investment Corp.
|
$602.40M | +2.3% | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| THEO | +0.1% | — | — | +0.1% | — |
| SPY | +0.1% | -0.4% | +15.1% | +0.4% | +12.9% |
| vs SPY | 0.0% | — | — | -0.3% | — |